Haemonetics (STU:HAZ) Research & Development: €51 Mil (TTM As of Mar. 2026)


STU:HAZ Haemonetics Corp STU:HAZ
25 GF Score
Price €65.50
GF Value €74.16
! 4 Warning Signs
View Full Analysis

What is Haemonetics Research & Development?

Haemonetics STU:HAZ 25 Research & Development is €51 Mil as of Mar. 2026. GuruFocus rates STU:HAZ with a GF Score™ of 25/100 and a GF Value™ of €74.16. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Haemonetics's Research & Development for the three months ended in Mar. 2026 was €12 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €51 Mil.

Haemonetics  (STU:HAZ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Haemonetics Research & Development Related Terms

Haemonetics Research & Development Historical Data

* Premium members only.

The historical data trend for Haemonetics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Research & Development Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.50 46.82 50.08 58.02 51.70

Haemonetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.93 14.10 12.67 12.12 12.50
STU:HAZ
25GF Score
Haemonetics Corp STU:HAZ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €51 Mil mean?
Haemonetics (STU:HAZ) has a Research & Development of €51 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Haemonetics and its competitors.
Is Haemonetics' Research & Development too high?
Haemonetics' current Research & Development is €51 Mil. Overall, Haemonetics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Research & Development compare to ITGR and IRTC?
Haemonetics' Research & Development of €51 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Haemonetics and its competitors. Haemonetics's current Research & Development is €51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Haemonetics (STU:HAZ) has a current Research & Development of €51 Mil. The stock's GF Value™ is €74.16, compared to a current price of €65.50 — trading 11.7% below its estimated fair value. The current Research & Development is €51 Mil. Haemonetics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Research & Development is €51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €65.50 is trading 11.7% below its estimated GF Value™ of €74.16.

Key valuation signals for STU:HAZ:

  • Research & Development: €51 Mil
  • GF Value™: €74.16 vs. price of €65.50 (11.7% below fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
25GF Score

Get the complete analysis for STU:HAZ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.50
Price
€74.16
GF Value